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Summary The survival experience of 582 women with premenopausal breast cancer was examined to
determine whether prognosis was related to body size or to demographic and reproductive factors.
During the follow-up period 228 patients died and 18 emigrated or were lost to follow-up. Usual body
weight, reported at the time of diagnosis, was a strong predictor of survival, with a statistically significant
trend towards lower survival with increasing weight. Height and obesity (Quetelet index) were not
significantly related to survival, although the tallest women and the most obese women appeared to fare
worst. Other characteristics of prognostic importance were disease stage and reproductive history (women
who were older when their first child was born fared better). Women aged 46-50 when diagnosed also
appeared more likely to survive but no clear trend with age was evident. Other characteristics of the women
including social class, cigarette use and oral contraceptive use were not significantly related to survival
probability.
In 1968, our group began a case-control study of
oral contraceptive use in young women with breast
cancer (Vessey et al., 1972). During the course of
the study, data were obtained from each woman
about height and usual weight and about a number
of characteristics known to be associated with
breast cancer risk. We have subsequently deter-
mined the survival experience of these women. In
this report, we describe our findings on the prog-
nostic importance of body size in premenopausal
breast cancer. We have also explored possible
relationships between survival probability and
various other risk factors, and these results are
given here as well.
Methods
The 582 patients included in the analysis were
enrolled in the case-control study between December
1968 and August 1977. At the time of enrolment
they were married (or had been married in the
past), aged up to 50 years, and receiving treatment
at one or other of 6 London hospitals for newly
diagnosed and histologically proven breast cancer.
A trained medical social worker or nurse inter-
viewed each patient about her medical, social,
obstetric, menstrual and contraceptive history. The
case notes of patients were examined (usually by
MPV) and clinical information was abstracted to
permit assignment of the tumour to a clinical stage
according to the TNM system (International Union
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Against Cancer, 1968). Pathology reports were
reviewed to determine whether cancer was found in
the axillary nodes at the time of surgical treatment.
Patients were followed annually to identify those
who died.
Recruitment procedures changed somewhat as
the case-control study continued. One of the six
hospitals was added in 1972 and the upper age limit
of patients was progressively increased (from 39
years until the end of 1971, to 45 years between
1972 and mid-1974, to 50 years thereafter). A more
detailed description of the methods used in the
study may be found in previous publications
(Vessey et al., 1972; 1983). The investigation also
included patients with breast cancer diagnosed after
August 1977 and from two hospitals in Oxford, but
these women are not included in the present
analysis since they were not designated for follow-
up. We also excluded from our analysis the 72
women who were post menopausal at the time of
diagnosis and the 27 for whom we had insufficient
staging data.
Patient survival was calculated from the date of
diagnosis until the date of death (228 patients), the
date of emigration or loss to follow-up (18 patients)
or the closing date of December 31, 1982. The
cumulative probability of survival was estimated
and plotted using actuarial methods. Rate ratios
and two-tailed tests of the statistical significance of
relationships between study variables and survival
were computed using the proportional hazards
method of Cox (Cox, 1972). Variables considered in
this analysis were: year of diagnosis, hospital,
tumour stage, axillary nodal status (histologically
positive versus histologically negative or not
reported), age at diagnosis, social class (as
determined by husband's occupation; for women
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without a husband no classification was allocated),
height, weight, Quetelet index (0.1 times the weight
in kilograms divided by the square of height in
metres), age at menarche, age at first birth, history
of miscarriage before first birth, oral contraceptive
use, cigarette smoking history and family history of
breast cancer. The hospital and year of diagnosis
variables were included because they might
confound the relationship between body size and
survival which was the principal focus of this
analysis.
Results
At the time of diagnosis the ages of the 582
patients ranged from 24 to 50 years (median 40
years). Their weights ranged from 87lb to 278lb
(median 133lb) and their heights from 49 inches to
74 inches (median 64 inches). (1 lb 0.45kg; 1
inch=25.4mm, SI equivalents). Sixty-two per cent
had clinical stage I tumours at first presentation
but histological examination of axillary nodes
showed that in 40% of patients the nodes were
invaded.
Table I shows the data on extent of disease
among patients grouped into five categories of
weight. The lightest women (up to 1121b) presented
less often with advanced disease as determined by
axillary nodal status or clinical stage, and overall,
there was a statistically significant trend towards
histologically positive nodes with increasing weight.
The survival experience of the women, grouped
by weight, is shown in Figure 1. Across the weight
Table I Extent of disease by weight at diagnosis
Weight in Pounds
. 112 113-126 127-140 141-154 >154 All
No. (%) with
positive axillary
nodes' 20 (32) 55 (36) 64 (35) 64 (50) 30 (53) 233 (40)
No. (%) at each
clinical stage
I 47 (75) 94 (62) 113 (62) 69 (53) 36 (63) 359 (62)
II 12 (19) 28 (19) 34 (19) 30 (23) 11 (19) 115 (20)
III+IV 4 (6) 29 (19) 35 (19) 30 (23) 10 (18) 108 (19)
Total 63 (100) 151 (100) 182 (100) 129 (100) 57 (100) 582 (100)
aP<0.01 test for trend of linear regression in proportions.
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Figure 1 Ten year survival of women in the 5 weight groups. Group 1, <1121b; Group 2, 113-1261b; Group
3, 127-140 lb; Group 4, 141-154 lb; Group 5, > 154lb. In comparing the data in the figure with the rate ratios
given in Table II, it should be remembered that the latter were computed using all the survival data.
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Table II Fatality according to weight, stage and other characteristics in women with
premenopausal breast cancer
Crude Statistical
rate Adjusted significance
Characteristic Range No. ratioa rate ratio' oflinear trendc
Weight
(in pounds)
Clinical stage
Age (yrs)
(at diagnosis)
Age at first term
birth (yrs)
History of
miscarriage
Age at menarche
(yrs)
Cigarette use
Oral contraceptive
use
Family history of
breast cancer
Husband's social class
(Registrar-General's
classification)
.112
113-126
127-140
141-154
_ 155
tIII
III&IV
<35
36-40
41-45
46-50
Nullip
20
21-25
.26
No
Yes
.12
13-14
>15
Never
Former
1-14/day
15/day
Never
Past
Recent
No
Yes
I-II
III
IV-V
No husband
63
151
182
129
57
359
115
108
138
166
203
75
83
94
176
229
533
49
232
255
95
288
64
112
118
352
133
97
528
54
217
243
65
57
1.0
1.1
1.4
1.5
1.9
1.0
1.9
3.1
1.0
1.0
1.0
0.7
1.0
1.1
0.8
0.7
1.0
1.2
1.0
0.9
1.2
1.0
0.9
0.8
1.0
1.0
0.9
1.0
1.0
0.9
1.0
0.9
1.0
0.8
1.0
0.9
1.2
1.3
1.7
1.0
1.9
3.0
1.0
1.0
0.8
0.7
1.0
1.4
0.9
0.7
1.0
1.0
1.0
0.9
1.1
1.0
1.0
0.8
0.9
1.0
0.9
1.0
1.0
1.0
1.0
0.8
1.0
0.7
P=0.011
P<0.001
NS
P =0.006'
NS
NS
NS
NS
NS
NS
aRatio of the death rate in a given category to that in the reference category (the first
group for each characteristic).
'Adjusted for the other characteristics listed as well as year of diagnosis and hospital of
diagnosis.
cOr result of test for heterogeneity for dichotomous variables.
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Table III Fatality according to height and Quetelet index in women with premenopausal
breast cancer
Statistical
Adjusted significance
Characteristics Range No. Rate ratioa Ratio ratiob oflinear trend
Height <62 inches 81 1.0 1.0
62-63 inches 151 1.5 1.5
64-65 inches 162 1.7 1.6 P=0.278
66-67 inches 123 1.4 1.3
.68 inches 65 1.9 1.8
Quetelet index .2.00 83 1.0 1.0
2.00-2.19 148 1.1 1.1
2.20-2.39 167 1.4 1.3 P=0.115
2.40-2.69 127 1.2 1.1
. 2.70 57 1.5 1.8
aRatio of the death rate in a given category to that in the reference category (the first
group for each characteristic).
bAdjusted for stage, age, social class, reproductive history, family history, cigarette use,
oral contraceptive use, year of diagnosis and hospital of diagnosis. Not adjusted for other
measures of body size.
groups there appeared to be a consistent pattern of
lower survival with increasing weight. The
estimated 5 year survival probability was 80% in
the group weighing under 1131b, 74% in those
weighing 113-1261b, 67% in those weighing 127-
1401b and in those weighing 141-1541b, and 55%
in those weighing over 154lb. The inverse
relationship between weight and survival
probability existed for all categories of clinical
stage.
Results of univariate and multivariate analyses of
survival determinants appear in Table II. Body
weight was significantly related to survival after
adjustment for the possible effects of other
variables, including clinical stage, but the
relationship was less strong than that shown in the
univariate analysis. As expected, clinical stage was
the strongest predictor of survival. The presence of
histologically proven cancer in the axillary nodes
was also an important predictor, but substituting
this variable for clinical stage in the model (or,
indeed, including both variables together) did not
materially alter the relationship between weight and
survival probability (data not shown). Other factors
that appeared to show a relationship with survival
were age at first term delivery and age at diagnosis,
although the test for trend was statistically
significant only for age at first delivery. Age at
menarche, tobacco use, oral contraceptive practices,
family history of breast cancer and social class were
not significantly related to prognosis.
In separate analyses, neither height nor Quetelet
index were significantly related to survival (Table
III). At the upper extremes, however, there did
appear to be an adverse effect, for the tallest group
died at 1.9 times the rate of the shortest group and
the most obsese group (as judged by the Quetelet
index) died at 1.5 times the rate of the least obese
group (or 1.8 times in each case after adjustment
for the effect of characteristics other than body
size). Between the extremes of height or obesity,
however, there was not a consistent pattern. We
also examined the relationship between weight and
survival while controlling for the effects of height
and Quetelet index (by including height and
Quetelet index in the analysis separately and
together). The results of these analyses suggested
that of the three body size measures, weight was
the most important predictor of survival.
Discussion
In this study of premenopausal breast cancer, body
weight was a strong and statistically significant
predictor of survival. Although height and Quetelet
index were less clearly related to survival, the tallest
women and the most obese fared worse than the
shortest women and the least obese. Thus our data
suggest that all three measures of body size (weight,
height and Quetelet index) may be inversely related
to survival, but in the present analysis the pattern
was consistent and statistically significant for
weight only.
Our findings are in accord with those from four
reported studies dealing with body size and risk of
recurrence in women with predominantly post-
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found that, among 2,627 patients treated for breast
cancer at one hospital, 5 year recurrence rates were
statistically significantly higher among heavier
women. Boyd et al. (1981) also observed a higher
risk of recurrence with increasing weight among 749
patients enrolled in a clinical trial of breast cancer
therapy. In that study, height did not appear to be
related to recurrence but Quetelet index was. In a
third study, based on 374 surgical patients in one
hospital, Tartter et al. (1981) noted a statistically
significant increase in disease recurrence for women
weighing more than 150lb. They also noted a
higher rate of recurrence in obese women, but the
difference was not statistically significant. Lastly,
no relationship between recurrence and obesity was
observed in a study of 106 women who had
undergone mastectomy at one hospital (Sohrabi et
al., 1980). No results were shown for weight or
height in the report of that study, and
interpretation of the findings was further
complicated by the relatively small number of
subjects followed up. Thus, the evidence from other
studies mainly supports our observation that
heavier women fare worse following breast cancer
treatment, but the evidence regarding height and
Quetelet index is uncertain.
Unlike other reported studies, our findings are
based on deaths rather than recurrences, so that a
biased assessment of outcome cannot account for
the effect we have observed. We included all 228
deaths in the analysis, and not just breast cancer
deaths, but in a group of women with this age
distribution one would expect only about 10 deaths
from causes other than breast cancer during the
follow-up period.
The clinical stage distribution of the tumours
occurring in our patients was generally favourable.
This may represent the influence of possible
selection factors (for example, women with
advanced disease being less likely to be referred to
the study hospitals or to be interviewed for the
case-control study) or may be due to over-
optimistic or incomplete recording of clinical
staging information in medical charts. We would
not expect either of these possibilities to result in a
spurious relationship between body size and
survival.
In our study, heavier women presented with more
advanced cancer than lighter ones, especially when
stage was assessed by the presence of histologically
positive axillary nodes. This observation may itself
be clinically important, for it suggests that breast
cancer in heavier women is more difficult to detect
at an early stage. Delayed diagnosis, of course,
shortens the computed time from diagnosis to death
and could produce an artifactual association
between weight and prognosis. Our findings are
only partially explicable on this basis because the
statistically significant relationship between weight
and survival persisted in the multivariate analysis
after adjustment for clinical stage or nodal status.
If, however, there is a general tendency for heavier
women to be understaged (perhaps because
metastases are less likely to be noticed) the result of
the multivariate analysis might still represent an
artifact. Thus, we cannot confidently distinguish
between (1) a biological effect of weight on
prognosis or (2) an effect of weight on delaying
diagnosis.
There is evidence from epidemiological studies
that weight is related to breast cancer mortality,
but the data are less clear regarding a relationship
between weight and breast cancer incidence. Lew &
Garfinkel (1979) observed a higher breast cancer
mortality rate in women who were heavier (relative
to the average weight for their height) in the
massive follow-up study organised by the American
Cancer Society. In an analysis of data from various
countries pertaining to mean body size and breast
cancer incidence and mortality rates, Gray et al.
(1979) found that weight was correlated with both
incidence and mortality but that correlations were
stronger with mortality. The results of case-control
studies of body size and breast cancer incidence are
conflicting and those studies that are positive tend
to indicate a relationship for postmenopausal
women only (Kelsey & Hildreth, 1983). Our
findings raise the possibility that the observation of
higher breast cancer mortality rates among heavier
women may be due, at least in part, to a worse case
fatality rather than a higher rate of disease
occurrence. Of course, body size might influence
both processes and Japanese women, who weigh
less on average than Western women, are less likely
to develop breast cancer and when they do get it
their survival is better (Morrison et al., 1976).
Obese postmenopausal women appear to differ
from leaner women in production and metabolism
of sex hormones (Kirschner et al., 1982). In this
regard, the data of Boyd et al. (1981) indicated that
the adverse effects of weight on breast cancer
prognosis were, perhaps, mitigated by ovarian
ablation and they and others (Donegan et al., 1978;
DeWaard, 1983) have suggested that hormonal
factors are likely to underlie the observed
relationship between weight and prognosis. Our
results show a relationship among women who were
premenopausal when diagnosed. In this group, non-
ovarian sources of oestrogen are apt to be less
important than in postmenopausal patients and our
findings may point away from an explanation that
involves oestrogen production by adipose tissue.
Our analyses revealed little relationship between
prognosis and other patient characteristics. In
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accordance with Morrison et al. (1972) we observed
no association between survival and measures of
social class. We also found no evidence for an
effect of age at menarche or history of miscarriage
before first delivery, but we did observe a possible
survival disadvantage for women with an early age
at first delivery. This finding is puzzling since the
effect is directly opposite to the protective influence
of early delivery on breast cancer incidence (Kelsey
& Hildreth, 1983). Morrison et al. (1972), did not
find any relationship between age at delivery and
survival and the results of other, smaller studies of
parity and prognosis have produced conflicting
results (Papatestas et al., 1980; Black et al., 1983).
Contrary to the suggestion of Daniel (1980)
cigarette use was not related to prognosis in our
patients. In an earlier analysis from our study,
based on 113 deaths, oral contraceptive users
appeared to have a more favourable survival than
non-users (Vessey et al., 1979). In a subsequent
analysis, involving longer observation time and
additional patients, this survival advantage was no
longer statistically significant (Vessey et al., 1983),
and in our current results, after yet further follow-
up (though confined to women with premenopausal
cancer) no appreciable difference in survival is
apparent. Our initial observation of better survival
among pill users was presumably due to chance.
In conclusion, our results and those of others
indicate that body size, particularly weight, is an
important predictor of breast cancer survival and
that the relatively poor survival of heavier women
seems only partially explicable by their tendency to
have more advanced disease at the time of
diagnosis. It is not clear whether height or obesity
independently contribute to prognosis. Our data
indicate that they may not, and we have some
doubt whether slimming will improve prognosis in
women with breast cancer, as some authors have
suggested (Donegan et al., 1978; DeWaard, 1983;
Wynder & Cohen, 1982). The role of nutritional
factors in survival requires further investigations
which might be performed most easily by following
up the cases who have participated in earlier studies
of diet and breast cancer aetiology. For the present
we would not generally advise the prescribing of
restrictive diets for patients, except in a research
setting, but we would favour the inclusion of body
size measurements as possible confounding
variables in future studies of breast cancer
treatment.
We thank the medical staff at the participating hospitals
for allowing us to study patients under their care and Mrs
E. Hilton, Miss K. Jones, Mrs M. Simmonds, Mrs J.
Young for conducting the interviews and following up the
patients. We are also grateful to the Medical Research
Council and the Imperial Cancer Research Fund for
financial support. Dr E.R. Greenberg was supported in
part while in Oxford by the Milbank Memorial Fund.
References
BLACK, M.M., HANKEY, B.F. & BARCLAY, T.H.C. (1983).
Parity as a prognostic factor in young breast cancer
patients. J. Natl Cancer Inst., 70, 27.
BOYD, N.F., CAMPBELL, J.E., GERMANSON, T.,
THOMSON, D.B., SUTHERLAND, D.J. & MEAKIN, J.W.
(1981). Body weight and prognosis in breast cancer. J.
Natl Cancer Inst., 67, 785.
COX, R. (1972). Regression models and life tables. J. R.
Stat. Soc. (B), 34, 187.
DANIEL, H.W. (1980). Estrogen receptors, breast cancer,
and smoking. N. Engl. J. Med., 302, 1478.
DEWAARD, F. (1983). Epidemiology of breast cancer: a
review. Eur. J. Cancer Clin. Oncol., 19, 1671.
DONEGAN, W.L., HARTZ, A.J. & RIMM, A.A. (1978). The
association of body weight with recurrent cancer of the
breast. Cancer, 41, 1590.
GRAY, G.E., PIKE, M.C. & HENDERSON, B.E. (1979).
Breast cancer incidence and mortality rates in different
countries in relation to known risk factors and dietary
practices. Br. J. Cancer, 39, 1.
INTERNATIONAL UNION AGAINST CANCER (1968).
TNM Classification of Malignant Tumours. Geneva,
U.I.C.C.
KELSEY, J.L. & HILDRETH, N.G. (1983). Breast and
gynecologic cancer epidemiology. Boca Raton, C.R.C.
Press.
KIRSCHNER, M.A., SCHNEIDER, G., ERTEL, N.H. &
WORTON, E. (1982). Obesity, androgens, estrogens and
cancer risk. Cancer Res., 42, 328Is.
LEW, E.A. & GARFINKEL, L. (1979). Variations in
mortality by weight among 750,000 men and women.
J. Chron. Dis., 32, 563.
MORRISON, A.S., LOWE, C.R., MACMAHON, B.,
RAVNIHAR, B. & YUASA, S. (1976). Some international
differences in treatment and survival in breast cancer.
Int. J. Cancer, 18, 269.
MORRISON, A.S., LOWE, C.R., MACMAHON, B.,
WARRAM, J.W. Jr. & YUASA, S. (1972). Survival of
breast cancer patients related to incidence risk factors.
Int. J. Cancer, 9, 470.
PAPATESTAS, A.E., MULVIHILL, M., JOSI, C.,
IOANNOVICH, J., LESNICK, G. & AUFSES, A.H. (1980).
Parity and prognosis in breast cancer. Cancer, 45, 191BODY SIZE AND SURVIVAL IN PREMENOPAUSAL BREAST CANCER 697
SOHRABI, A., SANDOZ, J., SPRATT, J.S. & POLK, H.C.
(1980). Recurrence of breast cancer: obesity, tumour
size and axillary lymph node metastases. J. Am. Med.
Assoc., 244, 264.
TARRTER, P.I., PAPATESTAS, A.E., IOANNOVICH, J.,
MULVIHILL, M.N., LESNICK, G. & AUFSES, A.H.
(1981). Cholesterol and obesity as prognostic factors in
breast cancer. Cancer, 47, 2222.
VESSEY, M.P., BARON, J., DOLL, R., McPHERSON, K. &
YEATES, D. (1983). Oral contraceptives and breast
cancer: final report of an epidemiological study. Br. J.
Cancer, 47, 455.
VESSEY, M.P., DOLL, R., JONES, K., McPHERSON, K. &
YEATES, D. (1979). An epidemiological study of oral
contraceptives and breast cancer. Br. Med. J., i, 1755.
VESSEY, M.P., DOLL, R. & SUTTON, P.M. (1972). Oral
contraceptives and breast neoplasia: a retrospective
study. Br. Med. J., iMi, 719.
WYNDER, E.L. & COHEN, L.A. (1982). A rationale for
dietary intervention in the treatment of
postmenopausal breast cancer patients. Nutr. Cancer,
3, 195.